UPDATE: ALR Technologies Announces Sales Guidance for Q4 2022, Q1 2023, and Completion of the GluCurve Pet CGM Manufacturing Agreement

Rhea-AI Summary

ALR Technologies SG Ltd. (OTCQB:ALRTF) has secured a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd for distributing Continuous Glucose Monitor (CGM) hardware in the animal health market. This exclusive deal is expected to boost product availability and sales significantly in 2023. For December and Q4 2022, ALRT anticipates sales between $145,000 and $155,000, with Q1 2023 projected at $450,000 to $600,000. The company plans to increase production capacity and will showcase GluCurve at upcoming expos to enhance market visibility.

Positive

• Secured exclusive distribution rights for CGM hardware in animal health market.
• Anticipated Q1 2023 sales projected to be significantly higher at $450,000 to $600,000.
• Plans to increase production capacity, enhancing future sales potential.
• Participation in major expos to boost brand awareness.

Negative

• None.

SINGAPORE, Dec. 29, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd (“Infinovo”) for the Continuous Glucose Monitor (CGM) hardware used in the GluCurve Pet CGM. The agreement gives ALRT the exclusive global rights to distribute the CGM hardware in the animal health market.

Additionally, the Company announces it anticipates December and fourth quarter of 2022 sales to be in the range of $145,000 and $155,000. The Company expects Q1 2023 sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.

“December reflects a turning point for ALRT as we look to close out the fiscal year with our first quarter of meaningful sales, along with an attractive gross profit,” said Sidney Chan, Chairman and CEO of ALRT. “We will be exhibiting the GluCurve Pet CGM at CES January 5^th-8^th and VMX (Veterinary Meeting and Expo) January 14^th-18^th which should bolster awareness around the Company and GluCurve. The number of available units will increase quarter over quarter throughout 2023 resulting in a significant rise in sales as it will enable our distribution partner, Covetrus, to launch GluCurve throughout the US, EU, and other key markets.”

About Infinovo Medical Co. Ltd:
Founded in 2016, Infinovo is an innovative medical technology company, focusing on developing an accurate and affordable CGM for patients which will be available for both Type 1 and Type 2 Diabetics.  https://infinovo.com

About ALR Technologies SG Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.

In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.

More information about ALRT can be found at www.alrt.com and https://sg.alrt.com.

Investor Contact
Investor Relations: ir@alrt.com
Animal Health Inquiries: animalhealth@alrt.com
Media: Media@alrt.com
US: +1 804 554 3500
Singapore: +65 3129 2924

ALR Technologies SG Ltd. Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future sales and revenues, expected levels of product inventory and demand, strategy for customer retention, growth, product distribution, market penetration and expansion, financial results and reserves, and strategy for risk management. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: failure to generate anticipated company and product awareness, inability to maintain production capacity sufficient to meet customer demand for product, increased manufacturing costs, decreases in product market price, economic, regulatory, practical or other impediments to anticipated market expansion, and insufficient product demand. More information on these risks and other potential factors that could affect our business, reputation, results of operations, financial condition, and stock price is included in our filings with the SEC and subsequent filings. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

FAQ

What is the significance of ALRT's agreement with Infinovo Medical Co. Ltd for ALRTF shareholders?

The agreement grants ALRT exclusive rights to distribute CGM hardware in the animal health market, which may enhance revenue prospects and shareholder value.

What are ALRT's expected sales figures for the fourth quarter of 2022?

ALRT expects sales to range between $145,000 and $155,000 for December and the fourth quarter of 2022.

What sales growth does ALRT project for the first quarter of 2023?

For Q1 2023, ALRT anticipates sales between $450,000 and $600,000, indicating strong growth potential.

How does the production capacity affect ALRT's future sales?

Increased production capacity is expected to lead to greater availability of products, which could significantly boost sales throughout 2023.

What events will ALRT attend to increase product visibility?

ALRT will exhibit the GluCurve Pet CGM at CES from January 5-8 and VMX from January 14-18, aiming to enhance brand exposure.